The potential of technological innovation and an increasingly international profile have been prominent elements in this sixth edition of Pharmintech just concluded on April 12, 2019. The international event dedicated to the pharmaceutical, nutraceutical, cosmeceutical and biotechnology industries was able to provide an exhaustive panorama of the sector’s cornerstones. The focus on technological innovation is undoubtedly important; cutting-edge instrumentation and machines for the processing and packaging of pharmaceutical products, as well as innovative and interesting solutions in the field of packaging. Important are the technologies for coding and marking, the new proposals in terms of management software and integration of technologies, elements that involve the digitization of the sector and draw attention to fundamental commitments such as serialization and the prospects for a more efficient future with integrated systems.
The aim is to rise to higher levels of performance of the industry in terms of quality, safety and sustainability, exploring in this perspective the new potential for the Life Science industry.
Above, three photos of our Farmores stand: visitors to the stand, a display of products made by the PrimaK7 machine and a part of the Farmores staff at the end of the event.
Exhibitors and visitors: attendance at Pharmintech
Attendance figures were excellent, up 10% on last year’s edition with a significant share of foreign companies, doubling compared to 2016. In figures, the sixth edition of Pharmintech hosted 321 companies, 36% of which came from countries across borders, confirming the international profile of our technologies and our industry sector. Good also the visitors, whose heterogeneous origin shows a progressive growth on foreign markets.
Enthusiasm and satisfaction were underlined by Antonio Bruzzone, President of Pharmintech Srl and General Manager of Bologna Fiere, and Sergio Dompé, President of Pharmintech Exhibition. On the eve of the event, Sergio Dompé, President of Pharmintech Exhibition, pointed out that this VI edition of Pharmintech was particularly important, also considering that our country is the first pharmaceutical producer in Europe with a market worth 44 billion euros.
Sector studies and market forecasts: the results of the Pharmintech Monitor conducted by the Pharmintech Exhibition Observatory and developed in collaboration with the UCIMA Study Centre
- The proposed data are based on a global framework of the pharmaceutical market; worldwide, annual pharmaceutical expenditure exceeds 1000 billion euros and the amount allocated to this sector is about 14% of the expenditure that each individual incurs on health. The global pharmaceutical sector has always been characterized by a trend of growth, more modest in the recent period of crisis, but already recovering, so much so that for the next three years the expectations are +3.6% (value close to the pre-crisis period of +4%).
- Four countries have markets above 50 billion euros, United States, Germany, China and Japan, 25 countries have markets above 5 billion euros. The African market, still in its development phase, deserves a special mention, and for this reason it is looked at with particular interest to identify new target countries.
- There has been a slight contraction in the ratio between pharmaceutical expenditure and GDP, linked by sector analysts, to three factors in particular: the growth in pharmaceutical expenditure for generic drugs; the reduction in public pharmaceutical health expenditure, particularly in the European area, and the increase in the share of world GDP coming from countries with low pharmaceutical expenditure.
- The main strengths of the pharmaceutical industry affect the multinational structure of the companies, capable of intra-group strategies functional to the diversification of production at world level; the high profitability of the sector, also motivated by the regulatory regime of reference, and the substantial investments in research and development, represent further decisive factors for the evolution of the sector. The comparison between the 15 largest pharmaceutical companies in the world and the most important Italian companies in the sector shows an interesting fact: compared to the large international giants with more significant gross margins, our top companies have lower margins but all the indices are growing.